PHARMACOGENETIC TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In May 2023, University of California San Francisco UCSF launched California's first Clinical Pharmacogenomics Program (CPP), integrating patient genomic data into healthcare decisions at UCSF Health. Led by Bani Tamraz, PharmD, PhD, and Lisa Kroon, PharmD, the program covers 15 genes and 56 drug therapies, enhancing treatment efficacy and safety through personalized medicine. Automated clinical decision-support systems in UCSF Health’s electronic records prompt genetic testing recommendations or inform drug regimens based on genetic insights.
• In February 2023, MyRx, a new service from UF Health developed by pharmacists at the University of Florida College of Pharmacy, offers virtual pharmacogenetic testing consultations. It aims to provide patients with a convenient way to interpret their test results and optimize drug therapy.
• In May 2023, PerkinElmer Inc., a global provider of technology and service solutions, launched Revvity, Inc. as an independent provider of science-driven solutions leveraging advancements in diagnostics and life sciences to improve global well-being. Previously under PerkinElmer, Inc., Revvity Inc. serves diverse industries including pharmaceuticals, biotechnology, diagnostic laboratories, academia, and governmental organizations. The company offers a range of products including reagents, consumables, assays, instruments, and software.
• In May 2022, Invitae, a medical genetics company, introduced its expanded Pharmacogenomics (PGx) Panel, including the specialized Invitae Pharmacogenomics Mental Health Panel and a clinical decision support tool (CDST). This launch positions Invitae as offering one of the most extensive PGx panels in the industry. The panel covers guidelines and evidence affecting numerous commonly used medications across various specialties such as primary care, cardiology, endocrinology, pain management, and oncology, in addition to mental health medications.
• In October 2022, PacBio, a biotechnology company, and Twist Bioscience Corporation, a synthetic biology and genomics company, introduced an initial lineup of pre-designed long-read gene panels through their Twist Alliance collaboration. These fixed panels are designed to efficiently and cost-effectively target specific genomic regions. Additionally, customers have the flexibility to customize and scale their own panels for sequencing using PacBio HiFi reads.